AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases and Annogen, the company behind ...
ST. LOUIS--(BUSINESS WIRE)--M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation enzyme replacement and gene therapies for lysosomal storage ...
“Our scientists will be presenting our most recent progress in novel therapeutic approaches, new vector development, genome editing strategies, improvement of biomanufacturing, as well as CAR-T cell ...
A study published last week presents a compact base editor that enables efficient in vivo delivery using a single adeno-associated virus (AAV) vector. The innovation, once approved in clinical trials, ...
Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Scientists have a new trick to tackle TDP-43: antibodies delivered via adeno-associated virus. In the September 3 Molecular Therapy, scientists led by Damien Nevoltris at AC Immune, Lausanne, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results